135 related articles for article (PubMed ID: 17062693)
21. HER-2/neu-Positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications.
Brown RE
Ann Clin Lab Sci; 2002; 32(1):12-21. PubMed ID: 11848612
[TBL] [Abstract][Full Text] [Related]
22. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
23. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
Winters ME; Mehta AI; Petricoin EF; Kohn EC; Liotta LA
Cancer Res; 2005 May; 65(9):3853-60. PubMed ID: 15867384
[TBL] [Abstract][Full Text] [Related]
24. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
Bergmann F; Breinig M; Höpfner M; Rieker RJ; Fischer L; Köhler C; Esposito I; Kleeff J; Herpel E; Ehemann V; Friess H; Schirmacher P; Kern MA
Am J Gastroenterol; 2009 Jan; 104(1):171-81. PubMed ID: 19098866
[TBL] [Abstract][Full Text] [Related]
25. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
[TBL] [Abstract][Full Text] [Related]
26. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
27. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
28. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.
Diehl KM; Grewal N; Ethier SP; Woods-Ignatoski KM
J Surg Res; 2007 Sep; 142(1):162-9. PubMed ID: 17612563
[TBL] [Abstract][Full Text] [Related]
29. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
30. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
Weng MS; Ho CT; Ho YS; Lin JK
Toxicol Appl Pharmacol; 2007 Jan; 218(2):107-18. PubMed ID: 17182072
[TBL] [Abstract][Full Text] [Related]
31. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
Lanza-Jacoby S; Miller S; Flynn J; Gallatig K; Daskalakis C; Masferrer JL; Zweifel BS; Sembhi H; Russo IH
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1486-91. PubMed ID: 14693742
[TBL] [Abstract][Full Text] [Related]
32. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
Bai T; Luoh SW
Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
[TBL] [Abstract][Full Text] [Related]
33. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
34. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
[TBL] [Abstract][Full Text] [Related]
35. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
Adhami VM; Malik A; Zaman N; Sarfaraz S; Siddiqui IA; Syed DN; Afaq F; Pasha FS; Saleem M; Mukhtar H
Clin Cancer Res; 2007 Mar; 13(5):1611-9. PubMed ID: 17332308
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K
Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
[TBL] [Abstract][Full Text] [Related]
37. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.
Merrick DT; Kittelson J; Winterhalder R; Kotantoulas G; Ingeberg S; Keith RL; Kennedy TC; Miller YE; Franklin WA; Hirsch FR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2281-8. PubMed ID: 16609045
[TBL] [Abstract][Full Text] [Related]
38. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
Dittmann KH; Mayer C; Ohneseit PA; Raju U; Andratschke NH; Milas L; Rodemann HP
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):203-12. PubMed ID: 17996386
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors.
Moroni M; Veronese S; Schiavo R; Carminati O; Sorensen BS; Gambacorta M; Siena S
Clin Cancer Res; 2001 Sep; 7(9):2770-5. PubMed ID: 11555591
[TBL] [Abstract][Full Text] [Related]
40. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers.
Thor AD; Edgerton SM; Liu S; Moore DH; Kwiatkowski DJ
Clin Cancer Res; 2001 Aug; 7(8):2415-24. PubMed ID: 11489821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
